近日,美国乔治梅森大学吴云涛、美国国立卫生院Eric O. Freed和中国医科大学附属第一医院尚红三位教授的联合团队发现PSGL-1抑制HIV病毒进程的机制。通过认识该机制的作用,有望发展出新一类抗艾滋病毒药物。 P选择…
药学院谭旭课题组与复旦大学周峰课题组、美国乔治梅森大学吴云涛课题组合作,通过高灵敏度深度覆盖蛋白质谱技术和病毒学研究发现人类细胞中的一种新型抗艾滋病毒蛋白PSGL-1(P-selectin glycoprotein ligand 1)。相关研究以Proteomicprofiling of HIV-1 infection of human CD4+ T cells identifies PSGL-1 as an HIVrestri...
HIVHIV infectionsDNA synthesisCELL membranesPSGL-1 has recently been identified as an HIV restriction factor that inhibits HIV DNA synthesis and more potently, virion infectivity. But the underlying mechanisms of these inhibitions are unknown. Here we show that PSGL-1 directly binds to cellular actin...
对于HIV DNA合成的早期抑制,PSGL-1通过与F-肌动蛋白结合并限制细胞肌动蛋白动力学发挥作用,显着地,该限制还扩展至病毒体中的肌动蛋白。据报道肌动蛋白是HIV病毒粒子中最丰富的蛋白质之一,通过破坏小分子的F-肌动蛋白网络可以促进病毒感染性,而PSGL-1则由于其主要的F-肌动蛋白稳定活性而被取消。该观察表明肌动蛋...
To systematically examine this modulation in HIV infection, we used isobaric tag-based mass spectrometry to quantify changes in the abundance of over 14,000 proteins during HIV-1 infection of human primary CD4+ T cells. We identified P-selectin glycoprotein ligand 1 (PSGL-1) as an HIV-1 ...
In viral infections that become chronic, such as HIV and hepatitis B and C, T cells progressively lose responsiveness, many T cells are eliminated by apoptosis, and surviving T cells are arrested in a functionally impaired, exhausted state. A loss of T cell responsiveness can also develop in ...
Basic Motifs Target PSGL-1, CD43, and CD44 to Plasma MembraneSites Where HIV-1 AssemblesJonathan R. Grover, a * Sarah L. Veatch, b Akira Ono aDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA a ; Department of Biophysics, University ...
首先,作者发现过表达PSGL-1分子并不阻断HIV-1病毒颗粒的释放(release),但会整合进入释放的子代HIV-1病毒颗粒,明显降低子代HIV-1病毒对靶细胞的感染;PSGL-1对子代病毒感染性的降低与病毒糖蛋白无关,携带HIV-1包膜糖蛋白或疱疹性口炎病毒G蛋白(VSVG),甚至缺乏包膜糖蛋白病毒的感染性都会受到PSGL-1的抑制(图2)。
Fig. 1 | Proteomic profiling of HIV-1 infection in human primary CD4+ T cells. 在这项最新的研究种,研究者发现,高水平的PSGL-1能够抑制病毒感染前期的DNA合成。更重要的是,在新产生的病毒释放时,PSGL-1能被一并包裹到释放的病毒中,从而进一步并更强烈地抑制新一轮的病毒感染。
一般而言,本发明涉及抗体,更具体而言,涉及P-选择蛋白糖蛋白配体-1(PSGL-1)调控剂的用途及其调控免疫应答和治疗传染病,癌症和免疫性和炎性相关疾病和病症的用途。 发明背景 由T淋巴细胞进行的免疫应答对于针对微生物保护宿主至关重要的,但是它们在慢性感染中会变成功能障碍的。有慢性病毒感染,诸如HIV和丙型和乙型肝炎...